CRISPR Therapeutics

Historical price data

CRISPR Therapeutics' mission is to develop curative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its landmark achievement is the approval of CASGEVY™ (exa-cel), the world's first CRISPR-based therapy, developed with Vertex Pharmaceuticals for sickle cell disease and beta thalassemia. The company's strategy leverages a fully integrated R&D and manufacturing infrastructure to advance a diversified clinical pipeline, including allogeneic CAR-T therapies for oncology and programs in regenerative medicine. CRISPR Therapeutics aims to sustain its first-mover advantage by expanding the applications of gene editing across multiple therapeutic areas.

A proprietary CRISPR/Cas9 gene-editing platform enabling precise DNA modifications, utilized for both ex vivo cell engineering (e.g., edited stem cells, allogeneic CAR-Ts) and the development of in vivo delivery systems to treat diseases directly inside the body.